drugset / Trial / NCT01533961

Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158

NCT01533961

Phase 1 Completed 136 enrolled Drugs for Neglected Diseases
RandomizedSingle-groupQuadruple-blindTreatment

Summary

This study is aimed at assessing the tolerability and pharmacokinetic parameters of SCYX-7158 in healthy volunteers. In animal models of both acute and chronic experimental Trypanosomiasis infections, SCYX-7158 shows highly promising efficacy.

Timeline

Start
2012-02
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Acoziborole Small molecule 20 mg Oral
Subject Acoziborole Small molecule 960 mg Oral
Subject Acoziborole Small molecule 1200 mg Oral